Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242465 | 0.85 | PDE5A (0.49) | PDE5AKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3243388 | 0.79 | PDE5A (0.71) | PDE5AKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3245414 | 0.76 | F2RL3 (0.67) | PDE5AKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL9278722 | 0.76 | PDE5A (0.62) | PDE5AKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1991640 | 0.75 | HDAC4 (0.56) | HDAC4HDAC6KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3239815 | 0.74 | F2RL3 (0.53) | PDE5AKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3243403 | 0.72 | F2RL3 (0.52) | PDE5AKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL14290109 | 0.72 | PDE5A (0.66) | PDE5AKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL29617026 | 0.68 | HDAC4 (0.64) | HDAC4HDAC6KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3232557 | 0.67 | KDM4E (0.62) | KDM4EALDH1A1HPGDNPSR1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418176-B1 | Pyrazole derivates, their preparation and their use in drugs | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-7300950-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2005-08-11 | — | — | US | disclosed |
| US-6897232-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1418176-A1 | Pyrazole derivates, their preparation and their use in drugs | Aventis Pharma Deutschland GmbH (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-0908456-B1 | Pyrazole derivatives, their preparation and their use in drugs | AVENTIS PHARMA GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-06-05 | — | — | US | disclosed |
| US-6162819-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-19 | — | — | US | disclosed |
| EP-0908456-A1 | Pyrazole derivatives, their preparation and their use in drugs | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3A, PDE3B, PDE5A | PDE5A 3/4885HDAC4 4439/4885HDAC6 4254/4885 |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3B, PDE3A, PDE5A | PDE5A 3/4885HDAC4 4197/4885HDAC6 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.